Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.CERC · Entity 4936 | Chief Financial Officer | January 22, 2018 | January 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date January 22, 2018 · Filed January 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2028-01-21 | Direct | 100,000 |
Reported balance
After 2018-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-22 · Grant · Acquired 100,000 · Balance 100,000 F1: 1/4 of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining 3/4 of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 36 months beginning on 22-Jan-2018 |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining 3/4 of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 36 months beginning on 22-Jan-2018
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2018 Filed Jan 24, 2018 12:59 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001562180-18-000414 · primarydocument.xml · derivative · entry 1 Morris Mariam E · CIK 0001383376 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-21 F1 · derivative.exercise_date: 1/4 of the shares subject to the Option shall vest on the first anniversary of the date of grant and the remaining 3/4 of the shares subject to the Option shall vest in equal monthly installments on each monthly anniversary date of the first vesting date over the following 36 months beginning on 22-Jan-2018 Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 22:06 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001562180-17-000407 · primarydocument.xml · derivative · entry 1 Morris Mariam E · CIK 0001383376 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: 8,333 of the shares underlying the option vested and became exercisable on the date of grant; 8,333 shares shall vest and become exercisable on the first anniversary of the date of grant, and 8,334 shares shall vest and become exercisable on the second anniversary of the date of grant, subject to the Reporting Person's continuous service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.